Psoriasis

Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.

Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.

As Psoriasis Awareness Month 2023 comes to a close, Dermatology Times is reviewing the top psoriasis headlines and news from August.

Patients with psoriasis treated with IL-23i and IL-17i had a decreased risk of developing pneumonia, otitis media, and upper respiratory tract infections.

Lauren Miller, MPAS, and T.J. Chao, MPAS, emphasized that clinicians need to be an advocate for patients and take that extra step to educate.

Researchers noted a lack of significant differences in access to biologics among different populations.

Alexandra Golant, MD, and Mona Shahriari, MD, shared pearls regarding the role of nonsteroidal topicals in the treatment of plaque psoriasis.

Experts in dermatology provide insight into the importance of multidisciplinary care in the management of patients with generalized pustular psoriasis (GPP).

Erin Boh, MD, shares her opinion on the importance of proactively stocking and streamlining generalized pustular psoriasis (GPP) medication pathways due to emergent care requirements of GPP.

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Laura Bush, DMSc, PA-C, provides an overview of systemic treatment options for patients with plaque psoriasis, highlighting the follow-up process once treatment has been implemented.

Investigators noted that there was not a marked increase, however, in keratinocyte skin carcinomas.

Patient and physician demographics were not significantly associated with discordance.

Following this week's Science of Skin media roundtable hosted by AbbVie, panelist and National Psoriasis Foundations President and CEO Leah Howard, JD, discusses the importance of advocacy and mental health in chronic skin conditions.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share take-home pearls on the management of plaque psoriasis, highlighting the use of topical treatment to simplify the treatment regimen.

Expert dermatologists discuss plaque psoriasis patient populations that may not be ideal candidates for PDE-4 inhibitor treatment, as well as gaps that remain in the plaque psoriasis treatment landscape.

Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.

Mark Lebwohl, MD, discusses the utility of spesolimab, the only FDA-approved treatment for the management of patients with from generalized pustular psoriasis (GPP), highlighting the rapid efficacy of this therapy.

Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.

This Psoriasis Awareness Month, Dermatology Times is looking back at the treatment and research landscape of 2023.

Jennifer Conner, MPAS, PA-C, and Lakshi Aldredge, MSN, ANP-BC, comment on approaches to escalating treatment of plaque psoriasis from topical therapy to systemic therapy and initiating that conversation with the patient.

Experts in dermatology review a case of a patient with plaque psoriasis concentrated on her hands and discuss taking the patient’s preferences into consideration when selecting treatment.

Five nurse practitioners and physician assistants review patient case presentations and discuss unmet needs in the psoriasis landscape.

Drs Alexandra K. Golant and Mona Shahriari review the efficacy data of roflumilast and tapinarof in the treatment of plaque psoriasis.

Expert dermatologists provide an overview of 2 newer topical treatments in the plaque psoriasis landscape, roflumilast and tapinarof.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, discuss metrics to determine clearance in plaque psoriasis and how the provider’s expectations may be different from the patient’s expectations.

Lakshi Aldredge, MSN, ANP-BC, discusses how speed of treatment response guides treatment selection for the patient, taking patient preference into consideration. Jennifer Conner, MPAS, PA-C, comments on treatment failure in plaque psoriasis.

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.